Breaking News Instant updates and real-time market news.

CRUS

Cirrus Logic

$57.01

-0.32 (-0.56%)

, POWI

Power Integrations

$73.90

-0.6 (-0.81%)

07:38
09/13/17
09/13
07:38
09/13/17
07:38

Apple reveal positive for Cirrus Logic, Power Integrations, says Stifel

Stifel analyst Tore Svanberg doesn't believe there were many surprises from Apple's (AAPL) product reveal event, though he notes there had been a lot of speculation around the digital audio interface dongle being excluded. However, Apple's website shows it is still included "in-box" for all three iPhone models, removing near-term risk of content loss for Cirrus Logic (CRUS), he said. He also sees the event as positive for Power Integrations (POWI), which he views as the best-positioned power management IC company to capitalize on Fast Charger adoption, Svanberg tells investors. He keeps Buy ratings on Cirrus and Power Integrations.

CRUS

Cirrus Logic

$57.01

-0.32 (-0.56%)

POWI

Power Integrations

$73.90

-0.6 (-0.81%)

AAPL

Apple

$160.86

-0.64 (-0.40%)

  • 13

    Sep

  • 08

    Nov

CRUS Cirrus Logic
$57.01

-0.32 (-0.56%)

08/18/17
KEYB
08/18/17
NO CHANGE
KEYB
Apple OLED iPhone to be hurt by lack of fingerprint sensor, says KeyBanc
KeyBanc analyst Andy Hargreaves,says that supplier checks indicate that Apple (AAPL) has not been able to add an optical fingerprint solution to its new OLED iPhone and has decided to ship the device without such a sensor. Hargreaves believes that this development will negatively impact the upcoming iPhone cycle and cause more bullish Apple investors to be disappointed. However, he is upbeat on the stock's risk/reward ratio in the near-term, as he thinks that "initial demand" for the OLED iPhone 8 will be strong. However, he remains upbeat on iPhone suppliers Broadcom (AVGO), Cirrus Logic (CRUS), Cypress Semiconductor (CY), and Skyworks (SWKS).
08/03/17
OPCO
08/03/17
NO CHANGE
OPCO
Perform
Cirrus Logic guidance suggests no major iPhone 8 content growth,says Oppenheimer
Oppenheimer analyst Rick Schafer notes that Cirrus Logic (CRUS) reported in-line Q1 and says he believes Q2 guidance confirms his view that significant gen/gen content growth in the Apple's (AAPL) iPhone 8 is unlikely. The analyst reiterates a Perform rating on Cirrus Logic's shares.
08/02/17
OPCO
08/02/17
NO CHANGE
OPCO
Supply chain to react positively following Apple results, says Oppenheimer
Oppenheimer analyst Rick Schafer expects the Apple (AAPL) supply chain to react positively, as Apple's guidance likely implies limited impact from any possible launch/production delays. Within the company's supply chain, the analyst continues to prefer content increase stories helping insulate from any demand softness versus expectations. His top picks in the Apple supply chain are content-driven growth stories Broadcom (AVGO) and Skyworks (SWKS). Schafer remains on the sidelines on Cirrus Logic (CRUS) and Qorvo (QRVO) heading into their respective prints tomorrow.
07/18/17
07/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Underweight from Equal Weight at Barclays with analyst Blayne Curtis saying he is "unconvinced" that AMD products will gain enough traction to support the current valuation. 2. ADP (ADP) downgraded to Equal Weight from Overweight at Barclays with analyst Darrin Peller citing valuation and the potential for lingering political driven uncertainty to impact bookings growth. The analyst lowered his price target for the shares to $105 from $110. 3. Cirrus Logic (CRUS) downgraded to Underweight from Equal Weight at Barclays with analyst Blayne Curtis saying the company's content story "stalls" in fiscal year 2019. 4. FMC Corporation (FMC) downgraded to Neutral from Buy at Seaport Global with analyst Michael Harrison saying competitor Bayer recently noted high inventories of crop protection chemicals in Brazil that creates a more cautious view of FMC's second half earnings. 5. Dominion Diamond (DDC) was downgraded to Hold from Buy at Gabelli and to Market Perform from Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
POWI Power Integrations
$73.90

-0.6 (-0.81%)

04/17/17
SIDC
04/17/17
INITIATION
SIDC
Neutral
Power Integrations initiated with a Neutral at Sidoti
05/08/17
SIDC
05/08/17
UPGRADE
SIDC
Buy
Power Integrations upgraded to Buy from Neutral at Sidoti
07/25/17
DBAB
07/25/17
DOWNGRADE
Target $75
DBAB
Hold
Power Integrations downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Ross Seymore downgraded Power Integrations (POWI) to Hold citing valuation with the shares up 30% in the last month. The analyst says he has no incremental knowledge to support or refute market speculation regarding a potential design win in the upcoming Apple (AAPL) iPhone. He keeps a $75 price target on the shares.
07/25/17
07/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Sell from Hold at Deutsche Bank with analyst Paul Trussell saying a "difficult and promotional selling environment along with segmentation challenges" weaken his confidence in the company's near-term results. 2. Snap (SNAP) downgraded to Neutral from Buy with analyst Kevin Rottinghaus citing monetization concerns and increasing pressure from Facebook (FB) competition. 3. Cytori Therapeutics (CYTX) downgraded to Neutral from Buy at B. Riley with analyst Andrew D'Silva citing the STAR trial results, which missed both primary and secondary endpoints. The analyst cut his price target for the shares to 50c from $2.30. 4. lululemon (LULU) downgraded to Hold from Buy at Stifel with analyst Jim Duffy citing valuation. 5. Power Integrations (POWI) downgraded to Hold from Buy at Deutsche Bank with analyst Ross Seymore saying he has no incremental knowledge to support or refute market speculation regarding a potential design win in the upcoming Apple (AAPL) iPhone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AAPL Apple
$160.86

-0.64 (-0.40%)

09/13/17
UBSW
09/13/17
NO CHANGE
Target $180
UBSW
Buy
Apple shares reacting in-line with historical norm, says UBS
UBS analyst Steven Milunovich said Apple shares are performing in-line with the stock's history after the company conducted its product launch presentation - down into the event and up or down a bit the day of the event. Historically, what happens next is the stock will be down for a few weeks before moving up heading into earnings. The analyst admitted there were few surprises but the event was still impressive and he said the product pricing, which he views as pushing the envelope, was higher than he expected. Milunovich reiterated his Buy rating and $180 price target on Apple shares.
09/13/17
KEYB
09/13/17
NO CHANGE
KEYB
Apple new iPhone 8/X launch largely in-line with expectations, says KeyBanc
KeyBanc analyst John Vinh says that the incremental features and enhancements associated with the new Apple (AAPL) iPhones announced are largely in-line with expectations. The analyst points out that Apple announced three new phones, with key features including facial identification, removal of the home button on the iPhone X, wireless charging, and fast charging. Vihn sees the new phone launch as most positive for Broadcom (AVGO), Cypress Semiconductor (CY), Integrated Device (IDTI), and Skyworks (SWKS).
09/13/17
FBCO
09/13/17
NO CHANGE
FBCO
Apple launch mostly as expected, says Credit Suisse
Credit Suisse analyst John Pitzer notes that Apple (AAPL) has announced four product updates largely in-line with expectations, and points out that semi companies in his coverage universe with exposure to Apple include Broadcom (AVGO), Micron (MU) and Texas Instruments (TXN).
09/13/17
OPCO
09/13/17
NO CHANGE
Target $35
OPCO
Underperform
Apple iPhone X reaffirms negative outlook for Synaptics, says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz says that as widely predicted, Apple (AAPL) indeed abandons the fingerprint sensor on the drastically redesigned OLED iPhone, the iPhone X. The analyst believes the redesign may cause an "existential crisis" for fingerprint-based authentication, with the iPhone X reaffirming his negative outlook for Synaptics' (SYNA) fingerprint sensor business in general. Uerkwitz expects Synaptics' exposure to the smartphone market and challenged competitive positions to pose revenue headwinds in the next 24 months. He reiterates an Underperform rating and $35 price target on Synaptics' shares.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$535.19

-28.21 (-5.01%)

05:26
09/20/17
09/20
05:26
09/20/17
05:26
Recommendations
AutoZone analyst commentary  »

AutoZone results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 30

    Oct

AGN

Allergan

$215.00

-6.54 (-2.95%)

05:21
09/20/17
09/20
05:21
09/20/17
05:21
Recommendations
Allergan analyst commentary  »

Allergan pipeline largely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TRVG

trivago

$10.99

-0.11 (-0.99%)

05:15
09/20/17
09/20
05:15
09/20/17
05:15
Recommendations
trivago analyst commentary  »

trivago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.